Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide

Lancet. 2005;365(9474):1873-5. doi: 10.1016/S0140-6736(05)66619-6.

Abstract

We describe three critically ill patients who received drugs with K(ATP) channel-opening properties and subsequently developed severe life-threatening complications, including hyperkalaemia and cardiovascular disturbances. Administration of the sulfonylurea-receptor inhibitor glibenclamide promptly reversed these abnormalities. Over the past 3 years, we have seen this syndrome and response in five patients taking nicorandil, ciclosporin, or isoflurane, which suggests that this disorder arises more frequently than is currently realised.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Adult
  • Critical Illness
  • Cyclosporine / adverse effects
  • Glyburide / therapeutic use*
  • Humans
  • Hyperkalemia
  • Hypotension
  • Isoflurane / adverse effects
  • Male
  • Middle Aged
  • Nicorandil / adverse effects
  • Potassium / blood
  • Potassium Channel Blockers / therapeutic use*
  • Potassium Channels / drug effects*
  • Potassium Channels / metabolism*
  • Syndrome
  • Vasodilation

Substances

  • Potassium Channel Blockers
  • Potassium Channels
  • Nicorandil
  • Cyclosporine
  • Adenosine Triphosphate
  • Isoflurane
  • Potassium
  • Glyburide